The phase 3 LITESPARK‑022 trial showed that combining belzutifan, a HIF‑2α inhibitor, with pembrolizumab significantly improved disease‑free survival versus control in patients with high‑risk clear‑cell renal cell carcinoma after surgery. Trial investigators presented the disease‑free survival benefit as the primary readout and outlined tolerability data. Belzutifan’s mechanism targets hypoxia signaling, and pairing it with PD‑1 blockade aims to deepen adjuvant control of micrometastatic disease. The companies behind the program plan regulatory discussions to define potential label expansion and next steps. The result introduces a new adjuvant regimen candidate in a setting with rising competition and highlights HIF‑2α inhibition as a viable axis in renal cell carcinoma management.